Delivery Order SPE2DB22D1103-SPE2DB25FTND3

Award Date 5/21/25
Potential Completion Date 5/22/25
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $1,578 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The order is for 4,565,768,520 units of the medication Mounjaro 15 mg/0.5 ml pen. The period of performance runs through September 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999 through December 2025. AmerisourceBergen, one of the largest...
The U.S. Defense Logistics Agency (DLA) awarded a $3,623.82 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The contract is for the supply of Mounjaro 5 mg/0.5 ml pens, with a completion date of July 19, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a wide range of...
The U.S. Defense Logistics Agency (DLA) awarded a $3,156 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, to provide the medication MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of March 12, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a $2,367.00 delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. This contract has an ultimate completion date of August 20, 2024. AmerisourceBergen, a for-profit organization, holds several Indefinite Delivery Contracts (IDCs) with DLA and other federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for delivering a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,462.55 contract is for the supply of the drug Mounjaro (2.5 mg/0.5 ml pen, 0.5 ml) and has an ultimate completion date of March 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $18,665.10 delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, and has a completion date of November 6, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which provides a...
This is a $29,022.72 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for the drug Mounjaro, a 10 mg/0.5 mL pen, with a completion date of May 28, 2025. AmerisourceBergen holds a substantial $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, allowing the company to supply a wide range of pharmaceutical products and medical supplies to support military...
The U.S. Defense Logistics Agency (DLA) awarded a $5,523 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 4565440991 - MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award has an ultimate completion date of August 14, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is valued at $21,606.55 and has an ultimate completion date of January 17, 2025. It is for the procurement of the drug Mounjaro, a 12.5 mg/0.5 mL pen with a 0.5 mL volume. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract, valued at $1,052.00, to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the provision of Mounjaro 15 mg/0.5 ml pens, a specialty pharmaceutical product. This delivery order is issued under an indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp, which has a potential value of $999,999,999.00 and a performance period through December 2025....
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB25FTND3
    Delivery Order

The U.S. government agency, the Defense Logistics Agency (DLA), awarded a $2,899.99 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Mounjaro 15 mg/0.5 ml pen. The contract has an ultimate completion date of May 22, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 8/20/25, 9:51 AM